Amendment No. 6, dated February 16, 2021
EX-10.1 2 exhibit101amendmentno6toba.htm EX-10.1 Document
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED
|AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT||1 CONTRACT ID CODE|
PAGE OF PAGES
1 | 3
2. AMENDMENT/MODIFICATION NO.
3. EFFECTIVE DATE
See Block 16C
|4. REQUISITION/PURCHASE REQ. NO.|
5. PROJECT NO. (If applicable)
|6. ISSUED BY CODE||ASPR-BARDA|
7 ADMINISTERED BY (If other than Item 6) CODE
200 Independence Ave., S.W.
Washington DC 20201
US DEPT OF HEALTH & HUMAN SERVICES
ASST SEC OF PREPAREDNESS & RESPONSE
ACQ MANAGEMENT, CONTRACTS, & GRANTS
O’NEILL HOUSE OFFICE BUILDING
Washington DC 20515
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP code)
|(x)||9A. AMENDMENT OF SOLICITATION NO.|
MODERNATX, INC 1492235
MODERNATX, INC. 200 TECHNOLOGY
200 TECHNOLOGY SQ
CAMBRIDGE MA 021393578
9B. DATED (SEE ITEM 11)
10A. MODIFICATION OF CONTRACT/ORDER NO.
10B. DATED (SEE ITEM 13)
|11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS|
☐ The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers ☐ is extended. ☐ is not extended.
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning ________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
12. ACCOUNTING AND APPROPRIATION DATA (if required)
|13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.|
A THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14. PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
|C. THIS SUPPLEMENTALAGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:|
D. OTHER (Specify type of modification and authority)
E. IMPORTANT: Contractor ☐ is not ☒ is required to sign this document and return 1 copies to the issuing office.
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Tax ID Number: 27-0226313
DUNS Number: 069723520
The purpose of this modification is to
1)Identify the batches/lots and doses that have been transferred from Moderna [***] to CDC or designee [***] and
2)Establish when PPQ activities become outside of the scope of this contract and will not be funded by BARDA.
This modification is not a funding action. All other contract terms and conditions remain unchanged.
Period of Performance: 04/03/2020 to 08/31/2023
Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect.
15A NAME AND TITLE OF SIGNER (Type or print)
Stephane Bancel, CEO
16A. NAME AND TITLE OF CONTRACTING OFFICER/Type or print)
/s/ Stephane Bancel
(Signature of person authorized to sign)
15C. DATE SIGNED
16B. UNITED STATES OF AMERICA
(Signature of Contracting Officer)
|16C. DATE SIGNED|
|Previous edition unusable|
STANDARD FORM 30 (REV 11/2016)
Prescribed by GSA FAR(48 CFR) 53.243
REFERENCE NO. OF DOCUMENT BEING CONTINUED
2 | 3
|NAME OF OFFEROR OR CONTRACTOR|
MODERNATX, INC 1492235
|Change Item 2 to read as follows (amount shown is tie obligated amount):|
|2||Base CLIN 0002 - Development of mRNA vaccine to BLA||0.00|
|2020.199COV1.25103 Appr. Yr.: 2020 CAN: 199COV1 Object Class: 25103|
|2020.199C014.25103 Appr. Yr.: 2020 CAN: 199C014 Object Class: 25103|
|NSN 7540-01-152-8067||OPTIONAL FORM 336 (4-86)|
Sponsored by GSA
FAR (48 CFR) 53.110
Page 3 of 3
1) The table below identifies the batches/lots and doses transferred under this contract from Moderna [***] to CDC or designee [***].
2) Identification of when PPQ activities become outside of the scope of this contract